37 completed, 7 unknown, 3 recruiting, 3 terminated. 24 Phase 2, 12 Phase 3, 11 Phase 1, 10 Phase 4, 3 Not applicable.
Follow Deferiprone: new trials by email Literature Review of Deferiprone trials Research Report on Deferiprone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia Deferiprone (DFP), N-Acetyl Cysteine (NAC) - Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder | Phase 2 | Recruiting | Amit Lotan | 80 | 2026-08-12 | 2026-09-29 |
| Early Screening and Treatment of Heart Complication in Sickle Cell Disease Deferoxamine, Deferasirox, Deferiprone - Sickle Cell Disease | Phase 2 | Recruiting | Inova Health Care Services | 100 | 2025-10-07 | 2026-09-09 |
| Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients Deferiprone Tablets, Placebo - Acute Myocardial Infarction Type 1 | Phase 2 | Recruiting | Rohan Dharmakumar | 89 | 2022-11-08 | 2026-09-29 |
| Ferritin and Iron Burden in SAH sIRB Deferiprone pill, placebo, Montreal Cognitive Assessment - SAH, Dementia | Phase 1 / Phase 2 | Active not recruiting | Duke University | 66 | 2020-10-01 | 2026-07-20 |
| Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage) - Iron Overload Due to Repeated Red Blood Cell Transfusions | Phase 2 | Completed | ApoPharma | 30 | 2019-03-06 | 2021-07-16 |
| Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Deferiprone, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | University Hospital, Lille | 372 | 2019-01-30 | 2025-12-05 |
| Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children Deferiprone oral solution, Placebo - Beta Thalassemia Major Anemia, Iron Overload | Phase 4 | Completed | Chiesi Canada Corp | 64 | 2018-11-09 | 2024-03-15 |
| Deferiprone to Delay Dementia (The 3D Study) Deferiprone 600mg delayed release tablets, Placebo Oral Tablet - Mild Cognitive Impairment, Prodromal Alzheimer's Disease | Phase 2 | Completed | Neuroscience Trials Australia | 81 | 2018-01-19 | 2024-07-03 |
| A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment Deferiprone, Placebo phase - Mild Cognitive Impairment | Early Phase 1 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2018-01-01 | 2018-02-06 | |
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Deferiprone, Acetylcysteine, Sitagliptin and Metformin - Diabetes Mellitus, Iron Metabolism Disorders | Phase 2 / Phase 3 | Unknown | Hadassah Medical Organization | 20 | 2016-12-01 | 2016-08-29 |
| Study of Parkinson's Early Stage With Deferiprone Deferiprone, Placebo - Parkinson's Disease | Phase 2 | Completed | ApoPharma | 140 | 2016-10-12 | 2024-04-10 |
| Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration Deferiprone 500Mg Tablet, Deferiprone 500 MG Oral Tablet [Ferriprox] - Bioequivalence | Phase 1 | Completed | SocraTec R&D GmbH | 25 | 2016-08-01 | 2016-12-07 |
| Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease Deferiprone, Placebo - Parkinson Disease | Phase 2 | Completed | University Hospital, Lille | 372 | 2016-02-09 | 2026-02-05 |
| Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients Deferiprone - Myelodysplastic Syndrome With Low-grade Lesions, Iron Overload Due to Repeated Red Blood Cell Transfusions | Phase 2 | Completed | Sheba Medical Center | 19 | 2016-02-01 | 2018-11-01 |
| Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers Deferiprone extended release, Deferiprone immediate release - Healthy | Phase 1 | Completed | ApoPharma | 20 | 2015-06-01 | 2016-02-26 |
| Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects Intravenous deferiprone, Placebo - Asymptomatic HIV Infection | Phase 1 | Completed | ApoPharma | 30 | 2015-06-01 | 2016-06-07 |
| Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Deferiprone - Iron Overload, Sickle Cell Disease | Phase 4 | Terminated | ApoPharma | 134 | 2015-05-21 | 2024-01-10 |
| Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers Deferiprone delayed release tablet formulation, Deferiprone oral solution - Healthy | Phase 1 | Completed | ApoPharma | 20 | 2015-05-01 | 2016-05-13 |
| Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml) desferal, ferriprox, blood transfusion - Beta-thalassemia, Serum Ferritin | Not applicable | Unknown | Ain Shams University | 50 | 2014-11-01 | 2015-01-14 |
| An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Deferiprone - Beta Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 64 | 2014-07-01 | 2015-01-14 |
Showing 20 of 55. Sign in to see all of them.
Iron Overload (16) · beta-Thalassemia (11) · Thalassemia (8) · Anemia, Sickle Cell (5) · Parkinson Disease (5) · Amyotrophic Lateral Sclerosis (3) · Hemochromatosis (3) · Pantothenate Kinase-Associated Neurodegeneration (3) · Cardiomyopathies (2) · Cognitive Dysfunction (2) · Dementia (2) · Friedreich Ataxia (2) · HIV Infections (2) · Acute Kidney Injury (1) · Alzheimer Disease (1)
ApoPharma (20) · University Hospital, Lille (5) · Ain Shams University (4) · Carelon Research (2) · Chiesi Canada Corp (2) · Children's Hospital of Philadelphia (2) · Consorzio per Valutazioni Biologiche e Farmacologiche (2) · Lipomed (2) · Amit Lotan (1) · Azienda Ospedaliera V. Cervello (1) · CorMedix Therapeutics (1) · Duke University (1) · Ente Ospedaliero Ospedali Galliera (1) · Hadassah Medical Organization (1) · Imperial College London (1)
United States (15) · Canada (12) · Italy (12) · Egypt (11) · France (8) · United Kingdom (8) · Germany (5) · Greece (3) · Israel (3) · Spain (3) · Australia (2) · Belgium (2) · Cyprus (2) · Indonesia (2) · Saudi Arabia (2)
Fernando Tricta, MD (6) · Arnold Munnich, M.D. (2) · David Devos, MD, PhD (2) · Elliott Vichinsky, MD (2) · Janet Kwiatkowski, MD (2) · Massimo Pandolfo, M.D. (2) · Mohsen S. Elalfy, professour (2) · Patricia J. Giardina, MD (2) · Thomas Klopstock, MD (2) · Alan R Cohen, MD (1) · Alan R. Cohen, MD (1) · Amal M El-Beshlawy, Prof. Dr. (1) · Antonio Piga, M.D. (1) · Ashley I. Bush (1)
PMID 37975597, PMID 24251381, PMID 29287521, PMID 11054091, PMID 16540422, PMID 17976187, PMID 18055982, PMID 18298856, PMID 18351337, PMID 18704280, PMID 19236376, PMID 20921906, PMID 20938663, PMID 20977930, PMID 21599434, PMID 21791473, PMID 22180427, PMID 2265118, PMID 23937987, PMID 25600572, PMID 25943368, PMID 27189756, PMID 27191165, PMID 27943621, PMID 28469157, PMID 29119631, PMID 29380903, PMID 30814647, PMID 31202468, PMID 32470438, PMID 32726602, PMID 33236783, PMID 33926431, PMID 34847228, PMID 34981144, PMID 36018224, PMID 36449420, PMID 37807937, PMID 37975798, PMID 39495531, PMID 39952690, PMID 39973479, PMID 8047081, PMID 8619408, PMID 8959943, PMID 9633879
U01HL065232 (2), U01HL065238 (2), U01HL065239 (2), U01HL065244 (2), U01HL065260 (2), 2008 (1), 2015 (1), 2017 (1), R01HL133407 (1), U01HL065233 (1)